How Bremelanotide Works: A CNS Approach to Desire

Bremelanotide and Sexual Health

1,267 women

Enrolled across two Phase 3 RECONNECT trials that led to FDA approval for bremelanotide in hypoactive sexual desire disorder.

Kingsberg et al., Obstetrics and Gynecology, 2019

Kingsberg et al., Obstetrics and Gynecology, 2019

View as image

Most drugs for sexual dysfunction target blood flow. Bremelanotide targets the brain. Specifically, it activates melanocortin-4 receptors (MC4R) in the hypothalamus, triggering dopamine release in brain regions that regulate sexual motivation.^[1] This makes bremelanotide fundamentally different from PDE5 inhibitors like sildenafil, which work on peripheral vasculature. Bremelanotide addresses desire itself, not the physical mechanics of arousal. For the full clinical evidence behind this FDA-approved peptide for HSDD, see the pillar article in this cluster.

Approved in 2019 as Vyleesi, bremelanotide is one of only two FDA-approved medications for hypoactive sexual desire disorder (HSDD) in premenopausal women.^[2] Understanding how it works requires a trip through the melanocortin system, a network of brain peptides and receptors that evolved to regulate everything from skin pigmentation to appetite to sexual behavior.

Understanding HSDD: the excitatory-inhibitory model

Hypoactive sexual desire disorder affects approximately 10% of premenopausal women in the United States.^[1] The current neurobiological model frames sexual desire as a balance between excitatory signals (primarily dopamine and norepinephrine) and inhibitory signals (primarily serotonin and endogenous opioids). In HSDD, this balance tips toward inhibition: either excitatory drive is too low, inhibitory tone is too high, or both.

This model explains why two very different drugs can treat the same disorder. Flibanserin (Addyi) works on the inhibitory side, reducing serotonergic suppression through 5-HT1A agonism and 5-HT2A antagonism. Bremelanotide works on the excitatory side, boosting dopaminergic drive through MC4R activation. Both rebalance the equation, but from opposite directions.

The distinction matters because women with HSDD are not a homogeneous group. Some may have excessive inhibition, some may have insufficient excitation, and some may have both. This is why response rates differ between drugs and why neither works for everyone.

The melanocortin system and sexual behavior

Melanocortins are a family of peptide hormones derived from a larger precursor molecule called proopiomelanocortin (POMC). Alpha-melanocyte-stimulating hormone (alpha-MSH) is the most studied member. These peptides bind to five melanocortin receptor subtypes (MC1R through MC5R), each with different tissue distributions and functions:

• MC1R: skin and hair (pigmentation). Found on melanocytes. Responsible for tanning.
• MC2R: adrenal glands (cortisol production). The ACTH receptor.
• MC3R: brain and immune cells. Involved in energy homeostasis and inflammation.
• MC4R: brain, predominantly hypothalamus. Regulates appetite, energy balance, and sexual function.
• MC5R: exocrine glands. Role in sebum production.

The connection between melanocortins and sexual function was discovered accidentally. In the 1990s, researchers testing Melanotan II (a synthetic alpha-MSH analog) for sunless tanning noticed that male volunteers developed spontaneous erections. This observation launched an entire field of research into melanocortin-mediated sexual response.

MC4R turned out to be the key receptor for sexual function. It is densely expressed in the medial preoptic area (mPOA) of the hypothalamus, a brain region that acts as an integration center for sexual motivation, arousal, and reward processing.^[1] For more on how dopamine modulates desire and motivation through peptide systems, see our dedicated article.

From alpha-MSH to bremelanotide

Bremelanotide is a cyclic heptapeptide, a synthetic analog of alpha-MSH. Its development followed a specific path:

1. Alpha-MSH is the natural melanocortin peptide, but it is rapidly degraded and lacks selectivity
2. Melanotan II was designed as a more stable analog for tanning research; its sexual side effects were unexpected
3. PT-141 (bremelanotide) was derived from Melanotan II specifically to target sexual function, with modifications to improve receptor selectivity and pharmacokinetics

Bremelanotide nonselectively activates MC1R, MC3R, MC4R, and MC5R, but at the therapeutic dose of 1.75 mg subcutaneous, MC4R activation in the hypothalamus is the primary driver of its sexual effects.^[2] The MC1R activity (which drives melanin production) explains why hyperpigmentation can occur with repeated dosing, a concern managed through the on-demand dosing schedule.

The hypothalamic mechanism: MC4R to dopamine

The proposed pathway, based on animal studies and human neuroimaging, works like this:^[1]

Step 1: Bremelanotide crosses the blood-brain barrier and reaches the hypothalamus after subcutaneous injection.

Step 2: It binds presynaptic MC4R on neurons in the medial preoptic area (mPOA) of the hypothalamus.

Step 3: MC4R activation triggers dopamine release in several interconnected brain regions: the nucleus accumbens (reward), the ventral tegmental area (motivation), the arcuate nucleus, and the medial and basolateral amygdala (emotional processing).

Step 4: Increased dopamine in these circuits enhances the excitatory component of the sexual response, increasing desire, motivation, and receptivity to sexual cues.

This is why bremelanotide's effects are on desire and motivation, not on genital blood flow. The peptide works upstream of physical arousal, in the brain circuits that determine whether someone wants sexual activity in the first place. This central mechanism distinguishes it from PDE5 inhibitors, which work through an entirely different pathway.

Animal studies have provided additional detail. In female rats, MC4R agonists increase solicitation behaviors (proceptive behaviors that signal sexual interest to males) without affecting lordosis (the reflexive posture for mating), reinforcing the distinction between desire/motivation and physical reflexes.^[1] The drug makes the animal actively seek sexual contact rather than simply being more responsive to it. Neuroimaging data in humans aligns with these animal findings: an fMRI study showed that bremelanotide enhanced sexual brain processing and increased self-reported desire for up to 24 hours after a single dose.

Evidence that the mechanism is central, not peripheral

The Diamond et al. (2006) study provided the clearest early evidence.^[4] Eighteen premenopausal women with sexual arousal disorder received intranasal bremelanotide or placebo in a double-blind crossover design. While watching sexually explicit videos:

• Subjective sexual desire increased significantly with bremelanotide vs placebo (P = 0.011)
• Satisfaction with arousal during intercourse within 24 hours was significantly higher (P = 0.026)
• Vaginal vasocongestion (blood flow) did not change compared to placebo

That last finding is the key. If bremelanotide worked by increasing genital blood flow (like Viagra), vaginal pulse amplitude would have increased. It did not. The drug increased desire and arousal perception without altering the peripheral vascular response. The effect was subjective, central, and motivational. Among women who attempted intercourse within 24 hours of treatment, significantly more reported satisfaction with their level of arousal following bremelanotide compared to placebo (P = 0.026), suggesting the central effect on desire translated into a subjectively better sexual experience.

The RECONNECT Phase 3 trials

Two identical Phase 3 trials randomized 1,267 premenopausal women with HSDD to bremelanotide 1.75 mg subcutaneous or placebo for 24 weeks.^[3]

Coprimary endpoints:

• Female Sexual Function Index (FSFI) desire domain score
• Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13

Results (integrated analysis):

• Desire score increased 0.35 points more with bremelanotide than placebo (P < 0.001)
• Distress related to low desire decreased 0.33 points more with bremelanotide (P < 0.001)
• Effects were consistent across both studies individually

The effect sizes are modest by absolute numbers, which is typical for central-acting drugs in psychiatry and sexual medicine. The clinical significance lies in the combination: increased desire paired with decreased distress about low desire. Both studies enrolled primarily white participants (85.6%) from US sites (96.6%), with a mean age of 39 years. The findings were consistent across age, weight, BMI subgroups, and baseline testosterone levels.

One detail worth noting: bremelanotide was used on-demand, meaning women self-injected before anticipated sexual activity. The average number of doses per month in the trials was approximately 2-3, not the maximum 8 allowed per label. This suggests most women found benefit without needing the drug frequently.

For details on the clinical evidence and how bremelanotide performed across subgroups, the pillar article covers the trial data in depth.

Safety and the neuroscience behind side effects

The side effect profile directly reflects bremelanotide's mechanism of action.^[5] Across 3,500 subjects in 43 studies:

Nausea (40% vs 1.3% placebo): MC4R activation in the area postrema and nucleus tractus solitarius (brainstem regions involved in nausea) explains this high rate. It is the same receptor, different brain location. Nausea typically diminishes with repeated use and was the most common reason for discontinuation.

Flushing (20.3% vs 1.3%): MC1R activation causes vasodilation and flushing. This is the same pathway responsible for tanning effects.

Transient blood pressure increases: Melanocortin receptors are involved in sympathetic nervous system regulation. Small, transient increases were observed on ambulatory monitoring but were not considered clinically significant in most patients. For a deeper look at the blood pressure concerns with melanocortin peptides, see our dedicated analysis.

Focal hyperpigmentation: MC1R activation stimulates melanocytes. This was rare with on-demand dosing (no more than once daily, no more than 8 doses per month) but occurred in over one-third of subjects who received up to 16 consecutive daily doses. This is why bremelanotide is approved for on-demand use, not daily administration.

Drug interactions: Bremelanotide lowered plasma concentrations of indomethacin and naltrexone. Most other drug interactions were not clinically significant.

On-demand dosing: a pharmacological design choice

Bremelanotide is self-administered subcutaneously at least 45 minutes before anticipated sexual activity.^[2] This on-demand model reflects several pharmacological realities:

• Peak effect timing: MC4R activation and downstream dopamine release take time after subcutaneous absorption
• Hyperpigmentation prevention: Limiting dosing frequency reduces MC1R-mediated skin darkening
• Nausea management: Each dose triggers nausea in many users; daily dosing would compound this
• Tolerance prevention: The melanocortin system can desensitize with continuous stimulation

This contrasts with flibanserin (Addyi), the other FDA-approved HSDD drug, which requires daily oral dosing for weeks before effects emerge. Flibanserin modulates serotonin receptors (5-HT1A agonist, 5-HT2A antagonist) to reduce the inhibitory brake on desire. Bremelanotide increases the excitatory signal. Same disorder, opposite pharmacological strategies.

What we know and what remains unclear

The mechanistic picture for bremelanotide is more complete than for most peptide drugs, but gaps remain:

Established:

• MC4R is the primary relevant receptor at therapeutic doses
• The mPOA of the hypothalamus is the key brain region
• Dopamine release in reward and motivation circuits drives the desire effect
• The mechanism is central (brain), not peripheral (genital blood flow)
• The RECONNECT trials confirmed efficacy in 1,267 women with HSDD

Unclear:

• The exact downstream signaling cascade from MC4R activation to dopamine release
• Why ~40% of women experience significant nausea while others do not
• Whether MC3R contributes meaningfully to the sexual effects at therapeutic doses
• How bremelanotide interacts with estrogen and testosterone signaling in the brain
• Whether the same mechanism applies in postmenopausal women (trials were premenopausal only)
• Long-term effects of repeated MC4R activation on receptor sensitivity

For how PT-141 is being studied for male erectile dysfunction and for a full overview of bremelanotide's known side effects, see the related articles in this cluster. And for context on how other melanocortin-targeting peptides like afamelanotide work through the same receptor family for entirely different indications, see our cross-cluster analysis.

The Bottom Line

Bremelanotide works by activating MC4 receptors in the hypothalamus, triggering dopamine release in brain circuits that regulate sexual desire and motivation. Early trials confirmed this is a central, not peripheral, mechanism: desire increased without changes in genital blood flow. The RECONNECT Phase 3 trials in 1,267 women validated the approach for HSDD, and the side effect profile (nausea, flushing, hyperpigmentation risk) directly traces back to melanocortin receptor activation in different body regions. Bremelanotide represents the only FDA-approved peptide that treats a neurological basis of sexual dysfunction rather than its vascular symptoms.

Frequently Asked Questions

How does bremelanotide work in the brain?

Bremelanotide activates melanocortin-4 receptors (MC4R) on neurons in the medial preoptic area of the hypothalamus. This triggers increased dopamine release in brain regions that process sexual motivation and reward, including the nucleus accumbens and ventral tegmental area (Pfaus et al., 2022). The effect is on desire and motivation, not on genital blood flow.

Is bremelanotide the same as Viagra?

No. Bremelanotide and Viagra work through completely different mechanisms. Viagra (sildenafil) inhibits PDE5 to increase blood flow to genital tissue, addressing the physical mechanics of arousal. Bremelanotide activates melanocortin receptors in the brain to increase sexual desire itself. In clinical trials, bremelanotide increased subjective desire without changing vaginal blood flow (Diamond et al., 2006).

Why does bremelanotide cause nausea?

Nausea occurs in about 40% of bremelanotide users because the same melanocortin-4 receptors (MC4R) that drive sexual desire in the hypothalamus are also present in brainstem regions that control nausea, specifically the area postrema and nucleus tractus solitarius (Clayton et al., 2022). The nausea typically diminishes with repeated use.

How long does bremelanotide take to work?

Bremelanotide is injected subcutaneously at least 45 minutes before anticipated sexual activity. Effects on desire can last up to 24 hours after a single dose. It is approved for on-demand use, not daily dosing, to minimize side effects like skin darkening that occur with frequent use (Dhillon and Keam, 2019).

What is the melanocortin system?

The melanocortin system is a network of peptide hormones (derived from proopiomelanocortin) and five receptor subtypes (MC1R through MC5R) found throughout the body. These receptors regulate skin pigmentation (MC1R), appetite and energy balance (MC4R), immune function (MC3R), and sexual behavior (MC4R). Bremelanotide's sexual effects come from MC4R activation in the hypothalamus (Pfaus et al., 2022).

Does bremelanotide work for men?

Bremelanotide is FDA-approved only for premenopausal women with HSDD. Early research showed that its predecessor Melanotan II caused erections in men, and some studies have explored PT-141 for male erectile dysfunction. The current approved formulation and indication are specifically for female hypoactive sexual desire disorder (Dhillon and Keam, 2019).